A Study to Compare the NexGen LPS and LPS-Flex Knee Implants

May 25, 2012 updated by: Zimmer Biomet

Prospective Randomized Multicenter Study of NexGen LPS-Flex Knee

The purpose of this study is to test for significant differences in functional outcomes obtained by using a NexGen LPS versus a NexGen LPS-Flex knee implant. Specifically, it is predicted that an increase in postoperative range of motion will be experienced by patients treated with the NexGen LPS-Flex knee implant.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study will compare the clinical results of the NexGen LPS femoral component with the higher flexion potential of the NexGen LPS-Flex femoral component in all patients with degenerative joint disease that require total knee arthroplasty. The primary variable of interest is postoperative range of motion achieved with the two devices, which are implanted with slightly different surgical techniques in patients who may also be subjected to different rehabilitation programs depending on the device they are assigned.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
331

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Quebec
      • Montreal, Quebec, Canada, h4j1c5
        • Hopital Du Sacre-Coeur de Montreal
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • University of Alabama at Birmingham
    • Georgia
      • Decatur, Georgia, United States, 30033
        • VA Medical Center
    • Illinois
      • Springfield, Illinois, United States, 62794
        • Southern Illinois University School of Medicine
    • Indiana
      • Indianapolis, Indiana, United States, 46260
        • Joint Replacement Surgeons of Indiana
      • Mooresville, Indiana, United States, 46158
        • The center for hip and knee surgery
    • North Carolina
      • Charlotte, North Carolina, United States, 28209
        • OrthoCarolina Research Institute
      • Durham, North Carolina, United States, 27710
        • Duke University Medical Center
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18103
        • VSAS Orthopaedics
      • Philadelphia, Pennsylvania, United States, 19141
        • Albert Einstein Healthcare Network
    • South Carolina
      • Greenville, South Carolina, United States, 29615
        • Piedmont Orthopaedic Associates
      • Spartanburg, South Carolina, United States, 29303
        • Orthopaedic Specialists of Spartanburg
    • Tennessee
      • Nashville, Tennessee, United States, 37232
        • Vanderbilt Orthopaedic Institute
    • Texas
      • Galveston, Texas, United States, 77555
        • Rebecca Sealy Hospital
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • The Rectors and Visitors of the University of Virginia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

21 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age, 21-80 years
  • Sex, Males and females will be included
  • BMI less than or equal to 39 and calf-thigh less than or equal to 90 degrees
  • Stable health, the patient would be able to undergo surgery and participate in the follow-up program based on physical examination and medical history.
  • Patient is willing and able to cooperate in follow-up therapy.
  • Patient exhibits preoperative radiographic evidence of joint degeneration consistent with TKA that cannot be treated in non-operative fashion.
  • Patient has stable and functional collateral ligaments.
  • Patient has potential to perform higher than average range of motion activities.
  • Operative side range of motion flexion greater than or equal to 90 degrees.
  • Severe knee pain and disability due to degenerative joint disease.
  • Patient or patient's legal representative has signed the Informed Consent form.

Exclusion Criteria:

  • Previous history of infection in the affected joint.
  • Previously failed knee endoprosthesis of any kind.
  • Charcot joint disease or other severe neurosensory deficits.
  • Previous patellectomy.
  • Patient is skeletally immature.
  • Grossly insufficient femoral or tibial bone stock.
  • Patient is pregnant.
  • Varus or valgus deformity greater than 20 degrees.
  • Fixed flexion deformity greater than 15 degrees.
  • Previous high tibial osteotomy.
  • Previous femoral osteotomy.
  • Patient is a poor compliance risk - currently treated for ethanol or drug abuse, physical or mental handicap, etc.
  • Loss of musculature or absence of musculoligamentous supporting structures required for adequate soft tissue balance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: 1
Study arm will consist of patients that are treated with the NexGen LPS-Flex Fixed Bearing Knee.
Device: NexGen LPS-Flex Fixed Bearing Knee
NexGen LPS-Flex Fixed Bearing femoral component
Other Names:
  • LPS-Flex Knee
Active Comparator: 2
Study arm will consist of patients that are treated with the NexGen Legacy Posterior Stabilized Knee.
Device: NexGen Legacy Posterior Stabilized Knee
NexGen Legacy Posterior Stabilized femoral component
Other Names:
  • LPS Knee

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Postoperative Range of Motion (ROM)
Time Frame: 6 Weeks to 2 Years Post-op, based on on the intervals listed
Postoperative ROM was calculated by taking the measurement of patient flexion minus the measurement of patients' extension.
6 Weeks to 2 Years Post-op, based on on the intervals listed

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Return to Function (RtF) Via Knee Society Score (Modified)
Time Frame: 6 Weeks to 2 Years Post-op, based on on the intervals listed

Scores were calculated from responses on a modified Knee Society Score by the enrolled subjects for the stated visit intervals.

Grading for the Knee Society Score is based on a scale from 0-100 and results are established follows: 80-100 =Excellent; 70-79 = Good; 60-69 = Fair; and Below 60 = Poor.
6 Weeks to 2 Years Post-op, based on on the intervals listed

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Zimmer Biomet

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 1, 2001

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2009

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2010

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 26, 2008

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 29, 2008

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 30, 2008

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 4, 2012

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 25, 2012

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 00-500

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings